Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other ...

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...

The financing effort, spearheaded by Goldman Sachs and Morgan Stanley, forms part of Sanofi’s strategy to divest its $20 billion consumer health business.

– Bolsters clinical pipeline and adds near-term value creation opportunities – – Licenses proprietary masking platform with goal of minimizing off-tumor toxicity and offering expanded ...

Sanofi is conducting a broad strategy review under Hudson, who took over as CEO on Sept. 1. He will give initial pointers on which businesses he wants to focus on at the investor day in Cambridge ...

Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the purchase of Cambridge-based Genzyme Corp. for $20.1 billion and will lead the company to further ...